⚕ GalenOps CRO console
← SITE005 (FRA)

SITE005-0047

withdrawn
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE005 (FRA) (Dr. Muller) · consented 2022-04-20
Adverse events
8
Serious AEs
3
Open data queries
0
Luna dropout signal
–

Adverse events

severe serious assessed 2026-08-18

Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-06-06 (study day 33); relationship: N; serious criteria: hospitalization

severe serious assessed 2026-08-18

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-07-05 (study day 62); relationship: N; serious criteria: hospitalization

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-02-17 (study day 289); relationship: N

mild assessed 2026-08-18

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-06-11 (study day 403); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-10-08 (study day 522); relationship: N

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-10-27 (study day 541); relationship: N

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-11-24 (study day 569); relationship: N

severe serious assessed 2026-08-18

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-12-17 (study day 592); relationship: not assessed; serious criteria: hospitalization

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.